Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
The GLP-1R and GIPR pathways both converge on beta cell function through incretin signaling, and retatrutide provides a tool to study the amplified incretin response that occurs when both receptors are activated simultaneously
Potential Regulatory Pathways If clinical trials continue demonstrating favorable safety and efficacy profiles, cagrilintide could potentially receive regulatory consideration for specific indications
Closest Analog: Cagrilintide + Semaglutide REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination in adults without diabetes
Please consult with us if you: Are pregnant or breastfeeding Have underlying health conditions Are taking certain medications Can this be part of a regular routine
US$ 23.37
US$ 29.05
US$ 25.03
US$ 21.07
